Comparative Pharmacology
Head-to-head clinical analysis: MECLOMEN versus PROFENAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MECLOMEN versus PROFENAL.
MECLOMEN vs PROFENAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meclomen (meclofenamate) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. This results in anti-inflammatory, analgesic, and antipyretic effects.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
50-100 mg orally every 6-8 hours; maximum 400 mg/day.
600 mg orally every 6 to 8 hours as needed for pain; or 1000 mg orally every 6 to 8 hours for antipyresis; maximum single dose 1000 mg, maximum daily dose 4000 mg.
None Documented
None Documented
Terminal elimination half-life: 0.8–1.1 hours for meclofenamic acid; 2–4 hours for metabolites. Short half-life requires frequent dosing (e.g., every 6–8 hours) for sustained effect.
6-8 hours (terminal); requires dosing every 6-8 hours to maintain therapeutic levels
Renal (approximately 70% as metabolites, <5% unchanged); fecal/biliary (approximately 30% as metabolites).
Primarily renal (approximately 70% as metabolites, <5% unchanged), biliary/fecal (30%)
Category C
Category C
NSAID
NSAID